Drugs / NASTORAZEPIDE CALCIUM
NASTORAZEPIDE CALCIUM
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01776463 | Jan → Apr 2013 | — | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00288925 | Sep 2005 → Dec 2007 | malignant pancreatic neoplasm | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02117258 | Apr 2014 → Jul 2016 | pancreatic adenocarcinoma | Zeria Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NASTORAZEPIDE CALCIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298135 ↗ |
| Known as | Nastorazepide hemicalcium | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298135 ↗ |
| Known as | R-(-)-z-360 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298135 ↗ |
| Known as | Z-360 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00288925 ↗ |
| Route | Oral | “Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal.” NCT02117258 ↗ |